Berry Mark, Kong Amanda M, Paredes Roger, Paone Julie, Shah Rohan, Taylor Rebecca, Mozaffari Essy, Gupta Rikisha, Gottlieb Robert L, Mateu Lourdes, Abdelghany Mazin, Goldman Jason D, Chokkalingam Anand P
Gilead Sciences, Inc., Foster City, CA, USA.
Aetion, Inc., 5 Penn Plaza, New York, NY, USA.
Sci Rep. 2025 Jul 28;15(1):27441. doi: 10.1038/s41598-025-06052-3.
Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospital chargemaster data linked to closed claims was queried for patients aged ≥ 12 years hospitalized for ≥ 2 days with COVID-19 between May 1, 2020, and September 30, 2021. Relative risk between remdesivir-exposed and unexposed patients was calculated for 16 individual Long COVID outcomes and a composite of any Long COVID outcome, occurring 90-270 days after hospital admission. Subgroup analyses occurred in immunocompromised patients. Regression models accounted for censoring, competing risks, and treatment assignment weights; statistical inferences were adjusted for multiple comparisons. Among 3,661,303 hospitalized patients, 52,006 with COVID-19 were included; 20,246 (38.9%) were immunocompromised. In the overall and immunocompromised populations, respectively, 33.0% and 29.5% received remdesivir; the composite of ≥ 1 Long COVID outcome occurred in 55.5% and 62.9%. Patients administered remdesivir experienced lower risk of any Long COVID outcome (risk ratio, 0.96; 95% CI 0.94-0.97; adjusted P < 0.001). Risk for several individual Long COVID outcomes was lower in those receiving remdesivir in the overall and immunocompromised populations. In conclusion, exposure to remdesivir was associated with a lower risk of Long COVID.
长期新冠是指在感染新冠病毒后出现的一种多系统综合征。这项回顾性队列研究调查了在新冠急性期使用瑞德西韦是否与降低长期新冠的发病率相关，包括在免疫功能低下的亚组中。我们查询了HealthVerity数据库，该数据库包含与已结案索赔相关的医院收费主数据，以获取2020年5月1日至2021年9月30日期间因新冠病毒住院≥2天的≥12岁患者。计算了瑞德西韦暴露组和未暴露组患者在入院90 - 270天后出现的16种个体长期新冠结局以及任何长期新冠结局综合指标的相对风险。对免疫功能低下的患者进行了亚组分析。回归模型考虑了删失、竞争风险和治疗分配权重；对统计推断进行了多重比较调整。在3661303名住院患者中，纳入了52006名新冠患者；其中20246名（38.9%）免疫功能低下。在总体人群和免疫功能低下人群中，分别有33.0%和29.5%接受了瑞德西韦治疗；出现≥1种长期新冠结局综合指标的比例分别为55.5%和62.9%。接受瑞德西韦治疗的患者出现任何长期新冠结局的风险较低（风险比为0.96；95%置信区间为0.94 - 0.97；校正P<0.001）。在总体人群和免疫功能低下人群中，接受瑞德西韦治疗的患者出现几种个体长期新冠结局的风险较低。总之，使用瑞德西韦与降低长期新冠的风险相关。
